Thomas F P
Neurologisches Institut, Columbia Universität, New York City, NY.
Nervenarzt. 1990 Dec;61(12):704-10.
Increased serum titers of antibodies against the ganglioside GM1 or its carbohydrate epitope Gal(B1-3)GalNAc have been associated with motor neuron disease, motor neuropathies with or without conduction block and sensorimotor neuropathies, whereas low level titers are part of the normal immune repertoire and are present in control groups and in neonatal blood. The target antigens of the antibodies are widely distributed and highly concentrated in the peripheral and central nervous system. The antibodies could damage neural tissue at several anatomic sites. Possible binding sites are the anterior horn cells in the spinal cord and the nodes of Ranvier. Reduction of serum titers with chemotherapy or plasmapheresis can lead to clinical improvement.
针对神经节苷脂GM1或其碳水化合物表位Gal（β1-3）GalNAc的血清抗体滴度升高，与运动神经元病、伴有或不伴有传导阻滞的运动神经病以及感觉运动神经病有关，而低滴度是正常免疫组成的一部分，存在于对照组和新生儿血液中。抗体的靶抗原广泛分布且高度集中于外周和中枢神经系统。这些抗体可在多个解剖部位损害神经组织。可能的结合部位是脊髓前角细胞和郎飞结。化疗或血浆置换降低血清滴度可导致临床症状改善。
